Last reviewed · How we verify

Hormone receptor-positive breast cancer — Treatment Landscape & Competitive Intelligence

Hormone receptor-positive breast cancer (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hormone receptor-positive breast cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
PF-07850327, ARV-471, vepdegestrant pf-07850327-arv-471-vepdegestrant Pfizer Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs) Estrogen Receptor (ER)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 1 drug in Hormone receptor-positive breast cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hormone receptor-positive breast cancer:

Cite this brief

Drug Landscape (2026). Hormone receptor-positive breast cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hormone-receptor-positive-breast-cancer. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing